About GENEOS Therapeutics
GENEOS Therapeutics is a private company based in Plymouth Meeting, Pennsylvania. It has reported $37,149,978 raised in four offerings on Form D since February 2019. Its chief executive is Niranjan Sardesai.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 31, 2023 | Apr 13, 2023 | $4,999,998of $9.9M target | 1 | $4.9M | EquityRule 506(b) | Form D ↗ |
| Mar 21, 2022 | Mar 28, 2022 | $17,249,984of $25.0M target | 9 | $1.9M | EquityRule 506(b) | Form D ↗ |
| Nov 12, 2020 | Nov 17, 2020 | $10,399,998of $11.9M target | 4 | $2.5M | EquityRule 506(b) | Form D ↗ |
| Feb 21, 2019 | Feb 27, 2019 | $4,499,998of $10.4M target | 3 | $1.4M | Equity, Options, Warrants to purchase Common Stock will be issued to M.M. Dillon & Co. and designees of Brookline Capital Markets in addition to any fees paid for commissions and financial advice.Rule 506(b) | Form D ↗ |
| Total, four offerings | $37,149,978 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on GENEOS Therapeutics's Form D filed Apr 13, 2023.
LH
Laurent Humeau
Director
JE
James Eadie
Director
NS
Niranjan Sardesai
Chief Executive Officer and director
SB
Samuel Broder
Director
SL
Sangwoo Lee
Director
CC
Casey Cunningham
Director
TF
Ted Fjallman
Director
Earlier filings also listed Joseph Kim (director, last listed Mar 2022), J. Kim (director, last listed Nov 2020) and Samuel Dr. Broder (director, last listed Feb 2019).